Connexion
E-mail
Mot de passe
Afficher le mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON
  1. Accueil Zonebourse
  2. Actions
  3. France
  4. Euronext Paris
  5. Crossject
  6. Actualités
  7. Autres langues
    ALCJ   FR0011716265

CROSSJECT

(ALCJ)
  Rapport
Cours en temps réel. Temps réel Euronext Paris - 06/12 13:37:38
2.39 EUR   -8.08%
02/11Rapport d'activité semestriel
PU
21/10CROSSJECT : Trophées INPI 2021
PU
19/10CROSSJECT : News - Octobre 2021
PU
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur CROSSJECT
03/12CROSSJECT : Validation of the ZENEO® Midazolam clinical batch
23/11CROSSJECT : American Epilepsy Society Annual Meeting
19/10CROSSJECT : INPI 2021 Awards
19/10CROSSJECT : team will be participating to the next CPhI Worldwide Conferences
05/10CROSSJECT : First-half 2021 results and business update
24/09CROSSJECT : H1 21: unsurprising (as usual)
23/09Crossject Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 202..
18/06CROSSJECT : Another good piece of news for the group
17/06A licensing agreement for Zeneo Hydrocortisone in the US and Canada (Crossject)
16/06CROSSJECT : US & Canada licensing agreement with Eton Pharmaceuticals for Crossject's ZENE..
16/06CROSSJECT : US & Canada licensing agreement with Eton Pharmaceuticals for Crossject's ZE..
16/06Crossject and Eton Pharmaceuticals Signed an Agreement for Zeneo® Hydrocortisone in the..
15/06ETON PHARMACEUTICALS : Pharma Secures US, Canadian Rights to Crossject's Zeneo Hydrocortis..
31/05CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant ..
06/05CROSSJECT : May 10-14, 21
08/04CROSSJECT : 2020 Annual results and business update
31/03CROSSJECT : FY20 unsuprising; waiting for more
30/03Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31,..
30/03Un perfume de fin de trimestre
30/03EN DIRECTO DESDE LOS MERCADOS : Alstom, ArcelorMittal, Vallourec, Quadient, Amazon, J&J, D..
09/03CROSSJECT : benefits from The French National Recovery Plan, with a €1.5 million grant
2020CROSSJECT : by the Human Factors and Ergonomics Society (HF
2020CROSSJECT : by the Human Factors and Ergonomics Society (HFES)
2020CROSSJECT : Biotech showcase Partnering
2020CROSSJECT : Stanley Caplan User Centered Product Design Award
2020CROSSJECT : January 11-15, 2021
2020CROSSJECT : successfully raises €12 million in funding
2020CROSSJECT : A double bond issue
2020Crossject Société Anonyme announced that it has received €5.24 million in funding from ..
2020CROSSJECT : Update on the group's business
2020CROSSJECT : First-half 2020 results and business update
2020Crossject Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 202..
2020CROSSJECT : appoints Don Zinn as VP US Business
2020CROSSJECT : Result of votes at Combined General Meeting of 25 june 2020
2020CROSSJECT : End of the conversion of convertible bonds in 2019
2020Crossject Société Anonyme announced that it will receive €5.24 million in funding from ..
2020CROSSJECT : No major changes after the release of the FY19 report
2020CROSSJECT : Meaningless FY19 results and product update
2020CROSSJECT : 2019 annual results and business update
2020CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant ..
2020CROSSJECT : Information relative au nombre de droits de vote et d'actions composant le cap..
2019CROSSJECT : Extra-financing to increase visibility
2019Crossject Société Anonyme announced that it has received €5.7 million in funding
2019CROSSJECT : A €2.6m non-dilutive issue
2019Crossject Société Anonyme announced that it has received €2.6 million in funding from I..
2019CROSSJECT : Cooperation agreement with the US Department of Defense
2019Crossject Société Anonyme announced that it has received €1.1 million in funding from B..
2018Crossject Announces Earnings Results for the First Half Ended June 30, 2018
2018CROSSJECT : On its way to reaching the market
2018Crossject Société Anonyme announced that it has received €2.3 million in funding from G..
2018Crossject Société Anonyme Reports Earnings Results for the Year Ended December 31, 2017
2018Crossject Société Anonyme cancelled the transaction announced on May 4, 2016
2018CROSSJECT : Financial calendar 2018
2018Crossject Société Anonyme announced that it expects to receive €5.25 million in funding
2017CROSSJECT : Interim 2017 results and business update
2017CROSSJECT : Business update
2017CROSSJECT : receives authorization to conduct Zeneo® Midazolam bioequivalence study
2017CROSSJECT : boosts its US commercial development efforts
2017CROSSJECT : boosts its US commercial development efforts
2016CROSSJECT - AFPRIC STUDY : patients approve needle-free injection.
2016Crossject Société Anonyme announced a financing transaction
2015CROSSJECT : Partnership agreement for ZENEO® Methotrexate in China with Xi'an Xintong Phar..
2015CROSSJECT : secures €6.7 million in funding for the development of three new drugs
2015CROSSJECT : CORRECTION: CROSSJECT enters into partnering agreement with Sayre Therapeutics..
2015CROSSJECT : 2015 half-year results & progress update
2015CROSSJECT : enters into partnering agreement with Sayre Therapeutics to commercialize ZENE..
2015CROSSJECT : Publication of the 3rd Letter to the shareholders
2015CROSSJECT : confirms the development plan for ZENEO® Sumatriptan
2014CROSSJECT : Appoints Henri de Parseval as Supply Chain Director